Mepolizumab Trial for EGPA/CSS Patients Now Enrolling

The purpose of this randomized, double-blind study is to investigate the efficacy and safety of mepolizumab (300 milligram mg administered subcutaneously every four weeks) compared with a placebo over a 52-week study treatment period in subjects with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA/Churg Strauss syndrome) receiving standard of…...

Read more

PROMIS – Quality of Life Survey

 Vivek Nagaraja, MD and Dinesh Khanna, MD, MSc at the University of Michigan Health System, are conducting a piece of research called PROMIS (Patient Reported Outcomes Measurement Information System) in rheumatology. The research involves an online survey catered to patients with various rheumatologic conditions. Interested patients are highly encouraged to…...

Read more

VCRC Genetic Repository One-Time DNA Study

The Vasculitis Clinical Research Consortium is pleased to let you know the University of Michigan, Ann Arbor is now enrolling patients for our study: VCRC Genetic Repository One-Time DNA Study About this study ~ The purpose of this study is to identify genes that increase the risk of developing vasculitis.…...

Read more

AAV Patients and Volunteers needed for a Clinical Trial in Vasculitis

Patients with anti-neutrophil cytoplasm antibody (ANCA)-associated Vasculitis (AAV) are at risk of disease relapse and so are often kept on long-term medication that suppresses their immune system. These medications may have possible long term harmful effects, but it is hard to tell when to stop treatment without risking disease relapse.…...

Read more

New VCRC Trial Enrolling Patients Now! The Assessment of Prednisone in Remission (TAPIR) Trial

This is a trial for patients with granulomatosis with polyangiitis (Wegener’s). You are invited to participate in a clinical trial being conducted by the Vasculitis Clinical Research Consortium (VCRC) under the direction of Dr. Peter Merkel, from the University of Pennsylvania Medical Center and VCRC Investigators at the University of…...

Read more